Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors
Related Experiment Video
Updated: Jul 2, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Tianrui Kuang1,2, Zhendong Qiu1,2, Kunpeng Wang1,2
1Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Background:
Immune checkpoint inhibitors (ICIs) represent a paradigm shift in the development of cancer therapy. However, the improved efficacy of ICIs remains to be further investigated. We conducted a systematic review and meta-analysis to evaluate the pan-immunoinflammatory value (PIV) and PILE score used to predict response to ICI therapy.
Methods:
We searched selected databases for studies on pan-immune inflammation values and their association with outcomes of treatment with immune checkpoint inhibitors. We used hazard ratios (HRS) and 95% confidence intervals (CI) to summarize survival outcomes. All data analyses were performed using STATA 15.0.
Results:
7 studies comprising 982 patients were included in the meta-analysis. The pooled results showed that higher PIV was significantly associated with shorter overall survival OS (HR = 1.895, 95%CI: 1.548-2.318) and progression-free survival (PFS) (HR = 1.582, 95%CI: 1.324-1.890). Subgroup analyses also confirmed the reliability of the results.
Conclusions:
High PIV and PILE metrics are associated with lower survival in cancer patients receiving ICIs.
